/

Società

T-

Non verificato

T-knife Therapeutics

Di cosa scriviamo

BiotecnologiaMedicina Salute Benessere

8 comunicati stampa

Guarda tutti i comunicati

17/11/2025

Biotecnologia

T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial for TK-6302, a Supercharged PRAME-targeted T Cell Receptor Therapy

Fonte

T-knife Therapeutics

Emittente

1.00

0

07/11/2025

Biotecnologia

Medicina Salute Benessere

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Fonte

T-knife Therapeutics

Emittente

1.00

0

07/10/2025

Biotecnologia

Medicina Salute Benessere

T-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress

Fonte

T-knife Therapeutics

Emittente

1.00

0

01/07/2025

Biotecnologia

T-knife Therapeutics Appoints Christoph Broja to its Board of Directors

Fonte

T-knife Therapeutics

Emittente

1.00

0

25/04/2025

Biotecnologia

Medicina Salute Benessere

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy

Fonte

T-knife Therapeutics

Emittente

1.00

0

25/03/2025

Biotecnologia

T-knife Therapeutics Announces Five Presentations at American Association for Cancer Research (AACR) Annual Meeting

Fonte

T-knife Therapeutics

Emittente

1.00

0

20/02/2025

Biotecnologia

T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors

Fonte

T-knife Therapeutics

Emittente

1.00

0

12/02/2025

Biotecnologia

T-knife Therapeutics to Participate in Two Investor Conferences in March

Fonte

T-knife Therapeutics

Emittente

1.00

0

Seguaci

0

Compatibilità

0